Methodology
How we evaluate evidence
Every peptide page on Pepteligence carries an evidence-strength label. This page explains exactly what that label means, where data comes from, and how we handle conflicts when sources disagree.
The five-tier evidence hierarchy
The compound holds FDA approval for a specific indication. Prescribing information (from DailyMed) is the primary source. Highest data quality — dosing, contraindications, and warnings are regulatory-grade.
Large-scale randomized controlled trials with placebo or active comparator. Strong causal evidence. Most peptides at this level are in late-stage clinical development or awaiting FDA review.
Early-phase human trials or well-replicated animal studies. Signals are promising but effect sizes in humans are not yet confirmed at scale. Dose ranges are approximate.
Retrospective studies, case series, or cohort data. Correlation, not causation. Useful for hypothesis generation and understanding real-world use patterns.
Community-reported experiences with no matched controls. We surface this data transparently because it represents real-world use — but label it clearly so readers calibrate appropriately.
Source priority order
When multiple sources cover the same claim, we display the highest-ranked source that speaks to it. Lower-tier sources are shown as supplementary context, never as the primary citation.
- 1
FDA prescribing information
DailyMed SPL — regulatory-grade, updated by the manufacturer
- 2
Peer-reviewed clinical studies
PubMed-indexed, with PMID or DOI for verification
- 3
Peer-reviewed preclinical research
Animal or in-vitro studies, labeled as such
- 4
Community-reported experiences
Structured submissions reviewed by a human moderator before appearing
How we handle conflicts
When sources disagree — for example, an animal study suggests a higher dose than a Phase 2 trial — we surface both, labeled clearly, rather than resolving the conflict ourselves. The higher-tier source takes precedence in the QuickFacts strip. The discrepancy is noted in the relevant section.
Community experiences are never used to override clinical data. They are displayed in a separate section and labeled as community-reported throughout.
Update cadence
FDA prescribing information is re-fetched from DailyMed whenever a new SPL version is published. Research content is reviewed and updated as new peer-reviewed studies are indexed. Community experiences are moderated within 48 hours of submission.
Each peptide page shows when it was last updated. If you believe a source is outdated or incorrect, email hello@pepteligence.com.
Evaluating peptide vendors
Searching for where peptides are sourced is common; recommending specific vendors is out of scope for Stage 1. Instead, we publish an educational checklist — COAs, testing methodology, red flags — so you can evaluate any supplier critically.
Vendor evaluation framework →Browse peptides by evidence tier
Every peptide in the catalog is labeled with one of the five tiers above. Start with the FDA-approved compounds for the highest-confidence data, or explore earlier-stage peptides with the appropriate level of skepticism.
Browse all peptides →